Clinical Trial Update: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating dose reduction of IL-17 and IL-23 inhibitors in psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriasis Vulgaris

Snippet

Sponsor: Radboud University Medical Center | Conditions: Psoriasis, Psoriasis Vulgaris | Phase 4 | Status: COMPLETED